Voglio sapere a riguardo di…

Federal Register / Vol. 86, No. 158 / Thursday, August 19, 2021 / Notices
lotter on DSK11XQN23PROD with NOTICES1

Control Act Act 12 U.S.C. 1817j and 225.41 of the Boards Regulation Y 12
CFR 225.41 to acquire shares of a bank or bank holding company. The factors that are considered in acting on the applications are set forth in paragraph 7
of the Act 12 U.S.C. 1817j7.
The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Banks indicated below and at the offices of the Board of Governors.
This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Boards Freedom of Information Office at https www.federalreserve.gov/foia/
request.htm. Interested persons may express their views in writing on the standards enumerated in paragraph 7 of the Act.
Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E.
Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 205510001, not later than September 3, 2021.
A. Federal Reserve Bank of Minneapolis Chris P. Wangen, Assistant Vice President 90 Hennepin Avenue, Minneapolis, Minnesota 554800291:
1. Daniel Otten, Hayward, Minnesota;
to retain voting shares of Minnesota Community Bancshares, Inc., Albert Lea, Minnesota, and thereby indirectly retain voting shares of Arcadian Bank, Hartland, Minnesota.
B. Federal Reserve Bank of Kansas City Jeffrey Imgarten, Assistant Vice President 1 Memorial Drive, Kansas City, Missouri 641980001:
1. Kathleen Sullivan, Cedar Rapids, Nebraska; to join the Sullivan Family Group, a group acting in concert, to acquire voting shares of Cedar Rapids State Company, and thereby indirectly acquire voting shares of Cedar Rapids State Bank, both of Cedar Rapids, Nebraska.
Board of Governors of the Federal Reserve System, August 16, 2021.
Michele Taylor Fennell, Deputy Associate Secretary of the Board.
FR Doc. 202117817 Filed 81821; 8:45 am BILLING CODE P

VerDate Sep<11>2014

17:28 Aug 18, 2021

Jkt 253001

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and Prevention Docket No. CDC20210088

Updating CDCs Contraception Guidance Documents: U.S. Medical Eligibility Criteria for Contraceptive Use and U.S. Selected Practice Recommendations for Contraceptive Use Centers for Disease Control and Prevention CDC, Department of Health and Human Services HHS.
ACTION: Notice with comment period.
AGENCY:

SUMMARY: The Centers for Disease Control and Prevention CDC in the Department of Health and Human Services HHS announces the opening of a docket to obtain comment on CDCs contraception recommendations. Two guidance documents, U.S. Medical Eligibility Criteria for Contraceptive Use US MEC and U.S. Selected Practice Recommendations for Contraceptive Use US SPR, provide evidence-based recommendations to assist health care providers when counseling patients on contraceptive choice and use. Updates to these guidance documents typically occur every 5 years. As part of the planning process for the next update, CDC is requesting public comment on content to consider for revision or addition to the recommendations and how to improve the implementation of the guidance documents. This action is necessary to consider multiple and diverse perspectives and ensure that the documents meet the needs of U.S.
health care providers and the persons they serve.
DATES: Written comments must be received on or before October 18, 2021.
ADDRESSES: You may submit comments, identified by Docket No. CDC2021
0088 by any of the following methods:
Federal eRulemaking Portal: http
www.regulations.gov. Follow the instructions for submitting comments.
Mail: insert complete mailing address, including mailstop Instructions: All submissions received must include the agency name and Docket Number. All relevant comments received will be posted without change to http regulations.gov, including any personal information provided. For access to the docket to read background documents or comments received, go to http www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Kathryn M. Curtis, Ph.D., Division of Reproductive Health, Centers for
PO 00000

Frm 00031

Fmt 4703

Sfmt 4703

46703

Disease Control and Prevention, 4770
Buford Highway NE, MS S1072, Atlanta, GA 30341. Telephone: 770
4885200. Email: usmecspr@cdc.gov.
SUPPLEMENTARY INFORMATION:
Public Participation Interested persons or organizations are invited to participate by submitting written views, recommendations, and data. CDC invites comments specifically on the following questions:
1. Are there existing US MEC or US
SPR recommendations that CDC should consider reviewing for possible revision, based on new evidence or other justification? Please provide references to new evidence and justification to support review of existing recommendations.
2. Are there new recommendations that CDC should consider adding to the US MEC? This could include eligibility criteria for contraceptive use among people with medical conditions or characteristics not currently included in the US MEC. Please provide references to supporting evidence, justification, and impact of new recommendations.
3. Are there new recommendations that CDC should consider adding to the US SPR? This could include clinical practice recommendations to address issues regarding initiation and use of specific contraceptive methods not currently included in the US SPR.
Please provide references to supporting evidence, justification, and impact of new recommendations.
4. Are there other issues that should be considered or suggestions to improve implementation of the US MEC and US
SPR recommendations to help ensure equitable access to contraceptive services such as better ways of presenting the recommendations, additional job aids or tools for providers, broader dissemination and implementation strategies, inclusion of additional partners, etc.? Please provide references to supporting evidence or justification.
Please note that comments received, including attachments and other supporting materials, are part of the public record and are subject to public disclosure. Comments will be posted on https www.regulations.gov. Therefore, do not include any information in your comment or supporting materials that you consider confidential or inappropriate for public disclosure. If you include your name, contact information, or other information that identifies you in the body of your comments, that information will be on public display. CDC will review all submissions and may choose to redact, or withhold, submissions containing
E:FRFM19AUN1.SGM

19AUN1